Maintaining Safe and Reliable Supply of Comparators during COVID19 As an agile, well-distributed and robust global supplier of Comparators for the biopharmaceutical industry, Inceptua is uniquely positioned to safely and…
Inceptua GroupApril 1, 2020
LUXEMBOURG – 23 March, 2020 – Inceptua – pharmaceutical company and service partner - and biopharmaceutical company Oxurion have announced a global license agreement for the commercialization of JETREA®, a…
Inceptua GroupMarch 23, 2020
In clinical trials, a Comparator drug, either an investigational or marketed product, is often required to determine the efficacy relative to a drug that is already on the market. Safe,…
Inceptua GroupMarch 22, 2020
Press release: Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA® Oxurion announces the signing of a JETREA® global license agreement with Inceptua Group. JETREA® is…
Inceptua GroupMarch 13, 2020
LUXEMBOURG / SAN FRANCISCO – 7th February 2020 – Inceptua, a global pharmaceutical company and service partner and Portola - US developer and manufacturer of therapeutic agents focusing on thrombosis…
Inceptua GroupFebruary 7, 2020
Inceptua has offices in both Japan and China where the regional Clinical Trial Services Team provides strategic sourcing and supply of clinical trial materials with associated clinical packaging and labelling…
Inceptua GroupFebruary 5, 2020
Dear Partner, It’s December, and the Holiday season is upon us. As we approach the turn of the year, we want to send our warmest wishes and our thanks for a wonderful…
Inceptua GroupDecember 18, 2019
NEWTOWN, PA., and LUXEMBOURG, Dec 6, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with…
Inceptua GroupDecember 6, 2019
To further strengthen its position as a leading pharmaceutical company and service partner, Inceptua appoints Paul Wituschek as President North America effective 1 January, 2020. Paul will take on the…
Inceptua GroupDecember 5, 2019